Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
5.00
+0.09 (1.83%)
At close: Jun 26, 2026, 4:00 PM EDT
4.900
-0.100 (-2.00%)
After-hours: Jun 26, 2026, 6:23 PM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Aclaris Therapeutics stock have an average target of 10.67, with a low estimate of 4.00 and a high estimate of 16. The average target predicts an increase of 113.40% from the current stock price of 5.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 8 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Initiates $13 | Buy | Initiates | $13 | +160.00% | Jun 1, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 | Buy | Maintains | $11 | +120.00% | May 11, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $12 | Buy | Reiterates | $12 | +140.00% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +220.00% | May 11, 2026 |
| Wedbush | Wedbush | Buy Maintains $10 | Buy | Maintains | $10 | +100.00% | May 8, 2026 |
Financial Forecast
Revenue This Year
5.71M
from 7.83M
Decreased by -27.00%
Revenue Next Year
5.36M
from 5.71M
Decreased by -6.20%
EPS This Year
-0.66
from -0.53
EPS Next Year
-0.83
from -0.66
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.0M | 11.2M | |
| Avg | 5.7M | 5.4M | |
| Low | 2.0M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 15.6% | 96.1% | |
| Avg | -27.0% | -6.2% | |
| Low | -74.4% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.49 | -0.51 | |
| Avg | -0.66 | -0.83 | |
| Low | -0.79 | -1.65 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.